Translational Genetics Research

This is a common critique of the genomic revolution. Indeed, beyond rare diseases and oncology, germline genetics has underdelivered on early promises around predicting disease risk, clinical outcomes, or drug response. With few noteworthy exceptions, for most complex traits, predictive performance remains modest. However, we massively underestimate the impact that human genetic studies have had on understanding disease biology and pointing to therapeutic opportunities, some of which have already translated into clinical benefit. Some examples: 👉 modern cardiovascular drug development has been largely shaped by targets, where variation in their genes has been linked to disease risk (PCSK9, APOC3, ANGPTL3, FXI, LPA, IL6 etc.) 👉 specifically, human genetic evidence has been translated to approved drugs for hypercholesterolemia (PCSK9, approved), boosted the clinical development of new categories of drugs (e.g. LPA, IL6, in phase 3), or informed new translational pathways and indications for others (e.g. FXI, awaiting approval for non-cardioembolic ischemic stroke) 👉 GWAS hits in Alzheimer's disease (e.g. TREM2, CLU, BIN1) have pointed to neuroinflammation and microglial biology, influencing drug development, even if clinical translation is still ongoing (TREM2) 👉 Similar story for ALS, where beyond pointing to Mendelian cases, for which targeted therapies are being developed, drugs emerging from GWAS hits are about to start being tested in clinical trials (UNC13A) 👉 many similar examples from autoimmune diseases, e.g. IL23/IL23R approved for psoriasis and inflammatory bowel disease, TYK2 inhibition approved for psoriasis now expanding to other indications, PTPN22/LYP emerging as a promising target in clinical development 👉 first approved drugs for dry age-related macular degeneration (C3 and C5 inhibitors) targeting the complement, were largely influenced by discovery of hits in several complement genes in GWAS 👉 the whole booming field of RNA therapeutics (especially liver-targeting) depends on sequencing the targets and so is directly linked to the human genome project So, even if prediction has not been proven as successful as originally thought, sequencing the human genome has had a tangible impact on understanding disease biology and quite an impact on delivering new medicines. The latter is expected to grow further, as the long-lasting pipelines of drug development deliver and more genetic discoveries get adopted. These contributions are often overlooked because the field was initially framed around the promise of "personalized medicine" and is now being judged against that specific promise, rather than against what it actually delivered.

24,000 Protein quantitative trait loci (QTLs): The Largest Proteogenomic Study Ever Conducted https://lnkd.in/gKduDRrz The largest proteogenomic study ever published just dropped — and it’s rewriting how we think about the genetic control of proteins in the blood. Across 78,664 participants in 38 cohorts, researchers identified over 24,000 protein quantitative trait loci (pQTLs) linked to 1,116 circulating proteins. That’s an unprecedented map of how our genes shape the protein landscape in circulation. A few standout findings: Using machine learning to assign effector genes, the team pinpointed which pathways, cell types, and tissues regulate circulating protein levels — flagging N-linked glycosylation as a key regulatory hub. They also drew a crucial distinction between cis pQTLs (genetic variants near the protein’s own gene, reflecting production/function) and trans pQTLs (distant variants that modulate protein levels indirectly). These two classes reveal fundamentally different biological stories — and different drug opportunities. On the translational side: plasma furin emerged as a candidate drug target in cardiovascular disease, and TYK2 inhibitors were flagged as a repurposing opportunity for rheumatoid arthritis — both supported by triangulated genetic and proteomic evidence. This is precision medicine infrastructure at scale — a proteogenomic atlas that connects genetic variation to protein biology to disease to druggable targets. #Proteogenomics #Proteomics #pQTL #DrugDiscovery #PrecisionMedicine #GeneticEpidemiology #CancerResearch #Genomics Figure Courtesy: Cell

🧬 𝗛𝘂𝗺𝗮𝗻 𝗴𝗲𝗻𝗲𝘁𝗶𝗰𝘀 𝗮𝘀 𝗮 𝗰𝗼𝗺𝗽𝗮𝘀𝘀 𝗳𝗼𝗿 𝗱𝗿𝘂𝗴 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 Clinical success rates in drug development remain low (~10%), despite advances in translational science. An intriguing large-scale study by Minikel et al., 2024 provides a very insightful measurement of how human genetic evidence shapes outcomes across the pipeline. 𝗙𝗶𝗻𝗱𝗶𝗻𝗴𝘀 𝗳𝗿𝗼𝗺 >𝟯𝟱𝟬,𝟬𝟬𝟬 𝗴𝗲𝗻𝗲–𝘁𝗿𝗮𝗶𝘁–𝗱𝗿𝘂𝗴 𝗮𝘀𝘀𝗼𝗰𝗶𝗮𝘁𝗶𝗼𝗻𝘀: * 𝟮.𝟲× 𝗵𝗶𝗴𝗵𝗲𝗿 𝗽𝗿𝗼𝗯𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗼𝗳 𝘀𝘂𝗰𝗰𝗲𝘀𝘀 when targets are supported by genetic associations. * 𝗦𝗼𝘂𝗿𝗰𝗲 𝗺𝗮𝘁𝘁𝗲𝗿𝘀: Mendelian evidence (e.g., OMIM) confers the strongest enrichment (~3.7×), while GWAS hits require high gene-trait confidence to be predictive. * 𝗣𝗵𝗮𝘀𝗲 𝗱𝗲𝗽𝗲𝗻𝗱𝗲𝗻𝗰𝗲: Genetic support is most impactful at Phase II → III transitions, the stage where mechanistic uncertainty is greatest. * 𝗟𝗶𝗺𝗶𝘁𝗲𝗱 𝗿𝗼𝗹𝗲 𝗳𝗼𝗿 𝗲𝗳𝗳𝗲𝗰𝘁 𝘀𝗶𝘇𝗲: Neither allele frequency, effect magnitude, nor publication timing significantly influence predictive power. * 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝘀𝗽𝗮𝗰𝗲 𝘃𝗮𝗿𝗶𝗮𝗯𝗶𝗹𝗶𝘁𝘆: Endocrine, metabolic, hematology, and respiratory areas benefit most (>3× success), while oncology shows smaller but still positive effects. * 𝗨𝗻𝗱𝗲𝗿𝗲𝘅𝗽𝗹𝗼𝗶𝘁𝗲𝗱 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆: Only ~4–5% of active clinical programs carry genetic support, and just ~1–2% of all genetically-supported gene–indication pairs have ever entered trials. 𝗜𝗺𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀: Systematic integration of human genetics into early-stage portfolio design is increasingly crucial. Prioritizing causal, high-confidence genetic evidence derisks target selection, optimize resource allocation, and improve attrition rates. Link:https://lnkd.in/eXJGFVzi

🟥 Patient-Derived Brain Organoids with Gene Repair for Neurodevelopmental Disorder Therapy Neurodevelopmental disorders, such as Rett syndrome, tuberous sclerosis complex (TSC), and some forms of autism spectrum disorder (ASD), often stem from genetic mutations that impair brain development, synaptic connectivity, and neural function. Traditional animal models and two-dimensional cultures cannot capture the unique complexity of human brain development. Recent advances in patient-derived brain organoids combined with gene repair technologies provide a powerful platform to model these disorders and develop personalized treatment strategies. By reprogramming patient somatic cells into induced pluripotent stem cells (iPSCs), scientists can generate three-dimensional brain organoids that mimic early human neurodevelopment. These organoids recapitulate key features such as cortical lamination, neuronal differentiation, and synapse formation. CRISPR-Cas9 and base editing technologies are then used to precisely correct disease-causing mutations in these organoids, such as MECP2 in Rett syndrome or TSC1/TSC2 in tuberous sclerosis. Gene-repaired organoids show significant improvements in neuronal maturation, synaptic density, and electrophysiological activity compared to uncorrected controls. These changes confirm functional rescue of the disease phenotype and validate gene-edited brain organoids as translational models for therapeutic development. In the long term, gene-repaired neural progenitor cells derived from these organoids could be used for autologous transplantation, providing a potential regenerative therapy with reduced risk of immunogenicity. In addition, the platform could be used to test gene-repaired neural circuits, drug responses, and drug delivery systems tailored to each patient's genetic background. In summary, gene-repaired patient-derived brain organoids represent the forefront of precision neurotherapeutics. They combine disease modeling, functional rescue, and personalized intervention in a single system, bringing new hope for treating previously intractable neurodevelopmental disorders. References [1] Simona Baldassari et al., Frontiers in Cell and Developmental Biology 2020 (doi: 10.3389/fcell.2020.590119) [2] Marcella Birtele et al., Nature Reviews Molecular Cell Biology 2024 (https://lnkd.in/eMAhzGQG) #BrainOrganoids #GeneRepair #NeurodevelopmentalDisorders #CRISPR #PrecisionMedicine #RettSyndrome #TuberousSclerosis #StemCellTherapy #Neurotherapeutics #OrganoidTechnology #PersonalizedMedicine #GeneEditing #NeuroscienceInnovation #FunctionalRescue #TranslationalResearch #CSTEAMBiotech

Unlocking a New Dimension of Gene Regulation: A Spatial Atlas of Alternative Polyadenylation A new preprint introduces the first spatially resolved atlas of alternative polyadenylation (APA) across 18 human tissues and 76 disease states. Using their new framework SpatialAPA, the authors map over 346,000 APA events in 52,000+ genes, offering a reference point for how cells regulate gene expression at the post-transcriptional level in health and disease. Key findings: ◾ APA regulation shows stronger organ-specificity than bulk gene expression, underscoring its role in tissue homeostasis and disease progression. ◾ In triple-negative breast cancer, spatial and single-cell analyses uncovered TSPAN8-positive epithelial subpopulations with unique APA regulation, linked to stemness, differentiation potential, and aggressive tumor behavior. ◾ An interactive online platform, SpatialAPAdb, now enables researchers worldwide to explore APA, gene expression, and cellular dynamics at spatial resolution. Drug development and translational science: APA has long been recognized as a fine-tuner of mRNA stability and translation. But until now, its spatial context in human tissue remained largely invisible. By integrating APA with spatial transcriptomics, this atlas provides: ▪️ New biomarkers: APA signatures may stratify patients, track disease progression, or predict therapeutic response. ▪️ Novel targets: Cell-type–specific APA regulation (e.g., in TNBC epithelial cells) highlights new vulnerabilities for intervention. ▪️ Mechanistic insights: Understanding APA’s role in cellular interactions and microenvironments could reshape how we view tumor heterogeneity, immune modulation, and tissue regeneration. This work sits at the frontier of spatial multi-omics. For oncology, it opens paths to precision strategies beyond genomics, capturing the interplay between transcriptional control and post-transcriptional regulation. For diagnostics, spatial APA may become a new layer of molecular fingerprinting. And for therapeutics, targeting APA-regulated pathways could expand the druggable landscape. The study not only expands our understanding of gene regulation but also equips the field with a community resource and analytical framework that will accelerate translational impact across oncology, immunology, and regenerative medicine. Read the full preprint here: https://lnkd.in/eBXUBpr8 #SpatialTranscriptomics #GeneRegulation #OncologyInnovation #DrugDevelopment #TranslationalResearch

Since the 1960s, the genetic code has been used to predict protein sequences from DNA and mRNA sequences.  Our Nature article demonstrates that these predictions miss thousands of protein sequences present in human tissues. Across >1,000 human samples, we identified numerous abundant proteins whose amino acid sequences differ from those predicted by the genetic code. These proteins are not rare translation byproducts. They accumulate to thousands of copies per cell. Some are more abundant than the proteins predicted by the genetic code from the same transcripts. Their abundance reflects a combination of alternate RNA decoding mechanisms — including codon-anticodon mismatches, tRNA abundance, and RNA modifications — and selective stabilization of the resulting proteins. The last factor – protein stability – emerges as a major determinant of protein abundance across proteins, proteoforms and cell types: https://lnkd.in/gHeScBNs Alternate RNA decoding is pervasive across functional groups of proteins, healthy and diseased tissues. It affects proteins playing key roles in neurodegeneration, and some alternately decoded proteins show strong enrichment in tumors compared to their surrounding tissues. The findings reveal a layer of proteome diversity that is largely invisible to DNA and RNA sequences alone. Our knowledge of the proteome remains relatively limited:  It is the next big Scientific Frontier https://lnkd.in/eDfJXesp and Parallel Squared Technology Institute is building tools to explore it. This discovery has been a long and exhilarating journey with Shira Tsour and the Slavov Lab team. It started in 2019 and proceeded through many challenges and thrilling highs. A journey that has opened new perspectives that we long to explore! 🔗 Links:  Nature Article: https://lnkd.in/gmNBXx-R OA version: https://lnkd.in/eqqJkg84  Science highlight: https://lnkd.in/esKDBq3B 

SpliceBio showed investors that oversized genes are solvable at the protein level. A new Cell paper argues the real leverage may be at the DNA level instead. If your disease gene is larger than ~4.7 kb, you are suddenly in “workaround” territory. Groups like SpliceBio are tackling this at the protein level, using inteins to splice two half-proteins back together inside the cell. It is clever biology, but you still see free fragments and variable efficiency. A new Cell paper takes a different angle: fix the problem at the DNA level instead. The authors call their system AAVLINK. Very simple idea: Split a large gene across two or three AAV vectors. Use a Cre/lox DNA recombination event inside the cell to stitch those pieces into one full-length gene. After the “surgery,” the Cre recombinase turns itself off using a weak promoter and smart vector design, so it does not keep cutting forever. Why should VCs and translational teams care? In head-to-head experiments, AAVLINK delivers more full-length protein and far fewer fragments than intein-based systems, including triple-vector formats for really big genes. It works on hard targets: full-length SHANK3 and SCN1A, as well as large CRISPR editors, all reconstituted in vivo with functional effects. In a Dravet (SCN1A) mouse model, AAVLINK improved Nav1.1 expression, survival, and seizure measures versus control. The effect is partial but real, telling us two things at once: the biology works, and better brain coverage and expression will be required for human-level impact. Cre is powerful and not without risk. High or prolonged Cre activity can cause DNA damage and cell loss, which is why recombinase-based therapies have been treated cautiously. This paper shows a thoughtful first pass at de-risking: Cre expression peaks early, then drops below detection once recombination is complete. A “2.0” version uses a weaker promoter and degron tag to make Cre even more transient, while preserving payload expression. But this is still “promising, not proven” on safety. Any clinical path will require deep work on rare recombination events, genome-wide DNA damage, and long-term tumor risk. To me, this is exactly the kind of platform work the field needs: It opens up monogenic diseases that have been structurally off-limits to AAV because the gene did not fit. It gives a fundamentally different knob to turn than protein or RNA splicing. It is already validated in relevant disease models, including Dravet, with room to grow as capsids, routes, and targeting strategies improve. If you are building or funding next-generation CNS or gene-editing programs, AAVLINK is not plug-and-play yet. But it is a serious signal that DNA-level recombination with a weak, self-limiting Cre can work in vivo for oversized genes. That is a space worth watching. If your pipeline has “too big for AAV” written in the margin, it might be time to revisit that list. Link in comments, unfortunately behind a paywall.

Extracellular vesicles: translational research and applications in neurology Brain-derived EVs (BDEVs) are promising blood biomarkers for a range of neurological disorders, including Alzheimer's, Parkinson's, stroke, traumatic brain injury, amyotrophic lateral sclerosis, and multiple sclerosis. These BDEV biomarkers hold potential across the therapeutic development pipeline, from target identification and disease monitoring to assessing treatment response in clinical trials, thus driving both forward and reverse translational research. Furthermore, the inherent properties and modifiability of EVs are being explored for innovative neurotherapeutic strategies, encompassing regenerative therapies and targeted drug delivery across the blood-brain barrier. This review was published in Nat Rev Neurol: https://lnkd.in/eqm4rZZy #genetics #genomics #precisionmedicine #genomicmedicine #brain #neurology #neuroscience #neurodegeneration #physiology #pathophysiology #neuroinflammation #raredisease #parkinson #alzheimer #ms #als #stroke #clinicaltrial #drugdevelopment #rna #microrna #mitochondria #regenerativemedicine #drugdiscovery #biotechnology #innovation #research #science #sciencecommunication

A good week for our lab as our paper in Science came out on 'First Release' at 2 pm. This one tackles the fascinating area of tRNA-derived fragments. Painstaking work by Guoping Li characterized one such fragment derived from Asp-GTC (Asp-GTC-3'tDR) as highly up-regulated in various cell types with stress. Notably this fragment is highly expressed in then kidney, heart and brain and appears to be a key regulator of autophagy. In metabolically active cells, it appears to be critical for homeostasis. Using ML tools we designed silencing LNA antimers to specifically silence this tDR and mimics to enhance expression. In two different murine models of kidney disease, silencing made kidney injury, inflammation and fibrosis worse, while delivery with polymer nanoparticles markedly ameliorated these processes. The mechanism appears to depend on the formation of stable RNA G-quad structures that both stabilize the tDR and allow for binding to an RNA modifying enzyme called PUS7 that regulates mRNA stability and RNA autophagy. Notably the tDR is similarly increased in human samples with early kidney disease, and we are now focused on seeing it translated as a therapy for kidney disease. Thanks to National Center for Advancing Translational Sciences (NCATS) who initially funded the work and NHLBI NIH for making the work possible. Check out the paper here: https://lnkd.in/ekihcf9F. Thanks to all our tremendous collaborators, Joseph Bonventre, Todd Lowe and many others for teaching and working with us on this.

Sidra Science Highlights 2025: 🧪 Story #2 - When a genetic mutation closes the "front door," science finds a side entrance! Keeping with the theme of #functional studies, today's paper is yet another demonstration of the level of depth required to go from discovering a #genetic variant to elucidating its #mechanism, i.e. to answer the question: What is that mutation actually doing to the patient? Today’s highlight comes from the Laboratory of Disease Modeling and Therapeutics, led by Dr. Luis R. Saraiva, Principal Investigator and Director of the Congenital Malformations Translational Research Program at Sidra Medicine The Challenge: The team identified a novel mutation in the AVPR2 gene in a child with Nephrogenic Diabetes Insipidus (#NDI), a rare kidney disorder causing severe dehydration. The question was: How exactly does this mutation lead to disease, and can we fix it? Lead authors Diogo Manoel and Idris Mohammed, PhD combined genetics with cell biology to find that the mutant receptor was completely misfolded and therefore destroyed by the cell before it ever reached the surface. The "front door" for signaling was gone. By dissecting the signaling pathway, the team showed that one could use a "receptor-independent" activator to trigger the same signaling pathway, 'bypassing' the broken receptor and successfully restoring the biological function! This functional analysis proved that the cell's internal machinery remains intact and targetable, opening the door for new pharmacologic strategies to treat the patient. Importantly, this study demonstrates the power of the Sidra Medicine ecosystem: astute clinician-scientists like khalid Hussain make a discovery in the clinic, then immediately team up with lab-based scientists like the Saraiva Lab to work it up—bridging the gap between a new diagnosis and optimized clinical care, all within the same building and same team. This is #PrecisionMedicine in action. 🌟 Special Recognition: This paper was selected for APSselect (December 2025) by the American Physiological Society, a distinction reserved for the "best of the best" in physiological research.🌟 Congratulations to the team: Diogo Manoel, Idris Mohammed, PhD, khalid Hussain, and Luis R. Saraiva 📖 Read the full paper in AJP-Endocrinology and Metabolism: https://lnkd.in/gPBFSN4P 🔗 Learn more about Dr. Saraiva’s Lab: https://lnkd.in/gJBPea_k #SidraMedicine #PrecisionMedicine #Endocrinology #RareDisease #KidneyDisease #APSselect #ScienceHighlights2025 Hamad Bin Khalifa University Yale University.